Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections
| Autor: | Alberto A. Carena, Martin E Stryjewski |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Methicillin-Resistant Staphylococcus aureus
medicine.medical_specialty medicine.drug_class Antibiotics Tetrazoles medicine.disease_cause 030226 pharmacology & pharmacy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Animals Humans Drug Interactions Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Oxazolidinones integumentary system business.industry Linezolid Skin Diseases Bacterial General Medicine Staphylococcal Infections Methicillin-resistant Staphylococcus aureus Dermatology Anti-Bacterial Agents chemistry 030220 oncology & carcinogenesis Skin structure Tedizolid business |
| Zdroj: | Expert Review of Clinical Pharmacology. 13:577-592 |
| ISSN: | 1751-2441 1751-2433 |
| Popis: | Acute bacterial skin and skin structure infections (ABSSSI) are among the most frequent infectious diseases. Recently, several new antibiotics with activity against MRSA have been approved. Tedizolid, a second-generation oxazolidinone approved for ABSSSI offers theoretical advantages over first-generation oxazolidinones.A comprehensive online search of Medline, ClinicalTrials.gov, and conference presentations was made, selecting articles between January 2000 and April 2020. In this review, the authors discuss the chemical and microbiological properties of tedizolid, summarize its efficacy, safety, and potential role in the treatment of ABSSSI as well as the potential for future indications.Tedizolid has proven to be non-inferior compared to linezolid for the treatment of ABSSSI in two registrational phase III clinical trials, being well tolerated. Tedizolid exhibits antibacterial activity against the most important ABSSSI pathogens (including multidrug-resistant strains of MRSA), as well as mycobacteria and Nocardia. It appears to have a safe profile, including decreased myelotoxicity and no significant drug interactions. Preliminary studies with longer duration of therapy seem to confirm these potential benefits. Overall, tedizolid expands the newly acquired armamentarium to treat ABSSSI. The role of tedizolid for other indications is under investigation and has yet to be determined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|